Preservation of Renal Function: The Key to Long-term Kidney Allograft and Patient Survival.

Slides:

Advertisements

Similar presentations

Defining Preimplantation Renal Allograft Quality Is biopsy: helpful or harmful? Michael J. Goldstein MD Director, Kidney/Pancreas Transplantation RMTI/Mount.

Advertisements

Terasaki Festschrift 2014 Clinical Relevance of Pre- and Post-Transplant HLA antibodies, Donor-Specific and Non-Donor-Specific HLA Antibodies Detected.

USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.

Monitoring HLA-specific antibodies

Prognostic significance of C4-positive vs. negative rejection Heinz Regele Heinz Regele Department of Pathology Innsbruck Medical University Heinz Regele.

DEFINING A NEW TOOL FOR LIMITING DELAYED GRAFT FUNCTION FOR KIDNEYS IN COLD STORAGE: THE MACHINE PRESERVATION TO COLD ISCHEMIA TIME RATIO Michael J. Goldstein.

The significance of Focal C4d+: The WU experience Helen Liapis, M.D. Professor of Pathology & immunology Kedainis RL et al. Am J Transplant Apr;9(4):812-9.

Hepatitis B virus infection in renal transplant recipients

Where Are We on the Path to Elimination of Chronic Hepatitis C?

2 Renal Unit, Belfast City Hospital, Belfast, BT9 7AB

Kidney Transplantation.

Mechanism and Treatment of Antibody-Mediated Rejection

Anand Yuvaraj International Transplant Fellow

CASE PRESENTATION DR SANJAY MAITRA, DR DENISH SAVALIA,

Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation Johann Pratschke, Duska Dragun, Ingeborg A. Hauser,

Number of Grafts Performed by Country

Volume 61, Issue 3, Pages (September 2014)

FIGURE 1 Trial profile. The safety population was defined as all randomly assigned patients who received at least one dose of study drug. All patients.

Hepatorenal Syndrome.

RISK RECOGNITION IN HEALTHCARE SETTINGS

Starting Strong: Initial Evaluation of the Patient With HCV

A Paradigm Shift in PAH.

Updates in Hodgkin Lymphoma

Glaucoma Progression.

Modern Strategies for Basal Insulin Use in T2D

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Neurogenic Orthostatic Hypotension: Expert Perspectives on Diagnosis and Treatment Strategies.

a b c d e Supplemental figure 4

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Risk factors in deceased-donor transplants Risk factor 1988

Metabolically Healthy Patients With Obesity

A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.

Updates in Pulmonary Arterial Hypertension

Are We Closer to Personalized Medicine in MS?

Seizures in the Elderly: Treatment and Special Considerations

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Oral Anticoagulation in AF

Examining the Latest Evidence in PAH

Mutational Testing to Select Novel Targeted Therapies in AML

Volume 82, Issue 5, Pages (September 2012)

ANZDATA Registry Annual Report 2013

ADVANCED PARKINSON'S DISEASE:

Primary Biliary Cholangitis

Volume 87, Issue 1, Pages (January 2015)

Program Goals Overview Is NEDA a Reasonable Target?

What's New in Therapeutic Options for Moderate to Severe RA?

When Is Intrathecal Drug Delivery Appropriate?

The Future of Lung Transplantation

Jayme E. Locke, MD, MPH American Journal of Kidney Diseases

New Strategies to Reduce HF Readmissions

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

An Observational Study on Thrombotic Microangiopathy in Renal Transplant Recipients - A Tertiary Care Centre Experience. Dr Sarang Vijayan Senior Resident.

Program Goals Disclaimers Defining Refractory Seizures.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Insulin in Diabetes Management: Effective Patient Selection Is Key

Clinical Challenges and Updates in Managing Seizure Clusters

Saving the Day.

Proteasome inhibitor-based therapy for antibody-mediated rejection

Program Goals Overview Is NEDA a Reasonable Target?

When Is Intrathecal Drug Delivery Appropriate?

Strategies for Infection Control in Cystic Fibrosis

Issues in Patients With Severe Epilepsy

Does rituximab help in HLA desensitization for kidney transplantation?

Volume 86, Issue 3, Pages (September 2014)

Volume 61, Issue 3, Pages (September 2014)

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

Deceased solid organ donors Recent trends from ANZOD

Presentation transcript:

Preservation of Renal Function: The Key to Long-term Kidney Allograft and Patient Survival

Kidney Allograft Failure

Expanded-criteria Donor

Kidney Donor Profile Risk Indicator

Pitfalls of Using the Kidney Biopsy to Predict Long-term, Deceased-donor Kidney Allograft Survival

Static Cold Storage vs Hypothermic Machine Perfusion of Deceased-donor Kidneys

DSA and Non-DSA HLA Antibodies

Predictors of the Development of DSA

Treatment of De Novo DSA-associated AMR

BKV Infection: The Leading Cause of Early Kidney Allograft Loss

Treatment Options for BKV Infection

Current CNI-sparing Strategies

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)